Unresectable Hepatocellular Carcinoma Clinical Trial
Official title:
SBRT Sequential TACE Combined With Sorafenib Versus Sorafenib Alone in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus：A Single-center Randomized Controlled Study
To evaluate and compare the efficacy and safety of SBRT sequential TACE combined with sorafenib versus sorafenib alone in the treatment of unreactable HCC with PVTT.
HCC Patients classified as BCLC stage C present with PVTT, and the recommended first-line treatment is systemic therapy with sorafenib according to updated Barcelona Clinical Liver cancer (BCLC) treatment algorithms.However, recent data from observational studies suggest that the combination of TACE and SBRT would be as effective as sorafenib. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT00988741 -
Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
|
Phase 2 | |
| Recruiting |
NCT03942328 -
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01900002 -
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT06315101 -
Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China
|
||
| Not yet recruiting |
NCT04947956 -
Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma
|
||
| Completed |
NCT01004978 -
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
Phase 3 | |
| Active, not recruiting |
NCT01217034 -
Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
|
Phase 2 | |
| Terminated |
NCT03695250 -
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02006030 -
Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03896646 -
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)
|
N/A | |
| Recruiting |
NCT05135364 -
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
|
Phase 2 | |
| Recruiting |
NCT06117891 -
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
|
||
| Recruiting |
NCT05957640 -
Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma
|
Phase 1 | |
| Recruiting |
NCT04736121 -
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
|
N/A | |
| Recruiting |
NCT05168163 -
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
|
Phase 2 | |
| Withdrawn |
NCT03345225 -
A Clinical Study of Precision TACE (P-TACE) With Surefire
|
N/A | |
| Recruiting |
NCT05667064 -
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
|
||
| Recruiting |
NCT05269381 -
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT02989870 -
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
|
Phase 1 |